Raphael Pharma to Acquire Bio-Gen Innovations

TL;DR

Raphael Pharma buying Bio-Gen Innovations, Q1 2025 close. Big pipeline boost incoming.

AI Summary

Raphael Pharmaceutical Inc. announced on December 23, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of common stock of Bio-Gen Innovations Ltd. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition is intended to expand Raphael Pharmaceutical's product pipeline and market reach.

Why It Matters

This acquisition could significantly bolster Raphael Pharmaceutical's position in the market by integrating Bio-Gen's innovative products, potentially leading to new revenue streams and increased shareholder value.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies, which could impact Raphael Pharmaceutical's financial performance.

Key Players & Entities

• Raphael Pharmaceutical Inc. (company) — Acquiring company
• Bio-Gen Innovations Ltd. (company) — Target company
• December 23, 2024 (date) — Date of agreement
• first quarter of 2025 (date) — Expected closing period

FAQ

Filing Documents

• ea0226291-8k_raphael.htm (8-K) — 30KB
• 0001213900-24-113467.txt ( ) — 199KB
• raph-20241223.xsd (EX-101.SCH) — 3KB
• raph-20241223_lab.xml (EX-101.LAB) — 34KB
• raph-20241223_pre.xml (EX-101.PRE) — 22KB
• ea0226291-8k_raphael_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On December 23, 2024, Raphael Pharmaceutical Inc. ("Raphael" or the "Company") received clinical study results after a successful completion of a proof-of-concept clinical study (the "Study"), evaluating the efficacy of the Company's Cannabinoid based formula ("Raphael's Formula") in patients with active Rheumatoid Arthritis ("RA"). The single-group Study was managed by MindMate, Inc./ dba Citruslabs ("Citruslabs") and conducted in Santa Monica, California, United States, under Institutional Review Board ("IRB") approval, in compliance with the United The Study evaluated the impact of Raphael's Formula on RA related health outcomes in 12 adult participants, each of whom used 0.5 mL Raphael's Formula product daily at home over an 8-week period, completed questionnaires and attended their local Quest Diagnostics Center for blood biomarker testing at designated intervals. According to the Study results, the questionnaires results demonstrated significant improvement in certain health parameters, including pain levels, sleep quality and overall well-being, with certain parameters remaining significantly improved through the end of the Study. The key findings from the Study results included a reduction in the Disease Activity Score (a comprehensive metric assessing RA disease activity) ("DAS28") by 19.2%, reflecting a total decrease from high to moderate disease activity. A low DAS28 score indicates reduced disease activity and is a key goal in RA management. Additionally, the percentage of participants classified according to disease activity was evaluated and the findings included an increase in the percentage of participants classified as in remission from 0% at baseline to 16.67% at week 8, an increase in the percentage of participants classified as having low disease activity from 8.33% to 16.67% and a decrease

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPHAEL PHARMACEUTICAL INC. By: /s/ Shlomo Pilo Name: Shlomo Pilo Title: Chief Executive Officer Date: December 30, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR